Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

599 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT).
Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J. Poynard T, et al. Lancet. 1998 Oct 31;352(9138):1426-32. doi: 10.1016/s0140-6736(98)07124-4. Lancet. 1998. PMID: 9807989 Clinical Trial.
Diagnosis and treatment of viral liver fibrosis.
Poynard T, Imbert-Bismut F, Munteanu M, Ratziu V. Poynard T, et al. Saudi J Gastroenterol. 2005 Jan;11(1):1-19. doi: 10.4103/1319-3767.33332. Saudi J Gastroenterol. 2005. PMID: 19861842
Biological markers of liver fibrosis and activity as non-invasive alternatives to liver biopsy in patients with chronic hepatitis C and associated mixed cryoglobulinemia vasculitis.
Sène D, Limal N, Messous D, Ghillani-Dalbin P, Charlotte F, Thiollière JM, Piette JC, Imbert-Bismut F, Halfon P, Poynard T, Cacoub P. Sène D, et al. Among authors: poynard t. Clin Biochem. 2006 Jul;39(7):715-21. doi: 10.1016/j.clinbiochem.2006.04.019. Clin Biochem. 2006. PMID: 16765932
Uses of error.
Poynard T. Poynard T. Lancet. 2002 Apr 27;359(9316):1514. doi: 10.1016/s0140-6736(02)08418-0. Lancet. 2002. PMID: 11988264 No abstract available.
FibroMAX: towards a new universal biomarker of liver disease?
Morra R, Munteanu M, Imbert-Bismut F, Messous D, Ratziu V, Poynard T. Morra R, et al. Among authors: poynard t. Expert Rev Mol Diagn. 2007 Sep;7(5):481-90. doi: 10.1586/14737159.7.5.481. Expert Rev Mol Diagn. 2007. PMID: 17892356 Review.
599 results